Investor Relations

Five Prime Therapeutics, Inc. discovers and develops innovative therapeutics to improve the lives of patients with serious diseases. Five Prime's comprehensive discovery platform, which encompasses virtually every medically relevant extracellular protein, positions it to explore pathways in cancer, inflammation and their intersection in immuno-oncology, an area of oncology with significant therapeutic potential and a growing focus of the company's R&D activities. Five Prime has promising product candidates in clinical and late preclinical development and has entered into strategic collaborations with leading global pharmaceutical companies.

Recent News > MORE
Date Title  
Monday, January 8, 2018 Five Prime Therapeutics Earns IND Milestone Payment Under Immune Checkpoint Pathways Discovery Collaboration with Bristol-Myers Squibb and Announces that BMS has Extended the Research Term of this Collaboration for a Second Time
Wednesday, January 3, 2018 Five Prime Therapeutics to Present at 36th Annual J.P. Morgan Healthcare Conference
Upcoming and Recent Events > MORE
Date Title  
Tuesday, January 9, 2018
4:30 PM PT
36th Annual J.P. Morgan Healthcare Conference
Supporting Materials
PDF January Corporate Overview  2.5 MB   Add to Briefcase
Thursday, December 14, 2017
11:30 AM ET
BMO Capital Markets Prescriptions for Success Healthcare Conference
Saturday, November 11, 2017
5:45 PM ET
Five Prime Therapeutics Conference Call
Supporting Materials
PDF View Presentation  2.6 MB   Add to Briefcase

FPRX (Common Stock)

Change (%)

Data as of 4:15 PM ET on Friday, January 12, 2018
Minimum 20 minute delay
Refresh quote
Powered By eSignal, Inc.